NEC Solutions America

NEC Corporation of America, which absorbed NEC Solutions America in 2006, is a major subsidiary of the global technology leader NEC Corporation, providing integrated IT, network, and biometrics solutions with a specialized focus on healthcare and life sciences. The company utilizes advanced artificial intelligence and machine learning through its "NEC Immune Profiler" platform to accelerate drug discovery and personalized medicine. In collaboration with partners like Transgene, NEC is developing individualized neoantigen cancer vaccines, including the clinical-stage candidate TG4050 for head and neck and ovarian cancers. Their healthcare portfolio also encompasses clinical workflow optimization, medical imaging analytics, and secure patient identification systems. By merging deep IT expertise with cutting-edge bioinformatics, the company plays a pivotal role in the parent company's strategic expansion into the biotechnology sector.